Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Electromicyn is a topical **Class IIb medical device** developed and manufactured by Te Arai BioFarma for wound care and skin disinfection. It consists of a stabilized, pH-neutral, hypotonic solution of reactive oxidizing species, including hypochlorous acid, peroxide, ozone, and superoxide, and is available in solution and hydrogel forms. Rather than acting through a discrete molecular target or conventional active pharmaceutical ingredient, it exerts broad-spectrum antimicrobial activity through physicochemical oxidative disruption of microbial outer membranes followed by osmotic rupture, with reported activity against bacteria, viruses, fungi, molds, spores, and biofilms. It is used as an antiseptic to disinfect, sterilize, irrigate, debride, and remove wound-associated biofilms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Electromicyn.